Deaths in Early AZT Trials
In the landmark 1987 placebo-controlled trial of AZT (BW 002/ACTG 002), 1 patient died in the AZT group compared to 19 deaths in the placebo group during the study period 1.
Trial Details and Mortality Data
The pivotal double-blind, placebo-controlled trial enrolled 282 patients with AIDS (manifested by Pneumocystis carinii pneumonia) or advanced AIDS-related complex 1. Patients were randomized to receive either:
- AZT group: 250 mg every 4 hours orally (n=145)
- Placebo group: (n=137)
Primary Mortality Findings
The mortality difference was striking and statistically significant (P <0.001):
- AZT recipients: 1 death
- Placebo recipients: 19 deaths
This dramatic survival benefit led to early termination of the trial 1. The study duration varied by patient, with 27 subjects completing 24 weeks, 152 completing 16 weeks, and the remainder completing at least 8 weeks.
Additional Clinical Benefits Beyond Mortality
Beyond the mortality reduction, AZT demonstrated:
- Reduced opportunistic infections: 24 infections in AZT group vs 45 in placebo group
- Improved functional status: Significant increases in Karnofsky performance scores (P <0.001)
- Weight gain: Statistically significant improvement (P <0.001)
- Immunologic improvement: Significant CD4 cell count increases (P <0.001), though this effect declined after 12 weeks in AIDS patients
- Partial reversal of anergy: 29% of AZT recipients vs 9% of placebo recipients (P <0.001)
Important Context
The FDA label confirms that "therapy with zidovudine has been shown to prolong survival and decrease the incidence of opportunistic infections in patients with advanced HIV-1 disease" 2. However, the label also notes that "a survival benefit for monotherapy with zidovudine was not demonstrated" in subsequent trials of asymptomatic or mildly symptomatic patients (ACTG 016 and ACTG 019), and that "subsequent trials showed that the clinical benefit of monotherapy with zidovudine was time limited" 2.
Critical Caveat
AZT monotherapy is no longer recommended or used in clinical practice. Modern HIV treatment requires combination antiretroviral therapy (ART). When used in combination regimens, zidovudine continues to demonstrate efficacy in reducing mortality and disease progression 2.
The question's premise about "progression-free survival not guaranteeing living longer" is contradicted by the early trial data, which showed clear mortality benefit in advanced AIDS patients receiving AZT versus placebo.